Primary Splenic Angiosarcoma with Liver Metastasis Caused by Malign Transformation of Hemangioma: A Case Report and Literature Review

Sözel, Hasan; Yılmaz, Fatih

doi:10.1007/s12029-020-00550-5

Cited by 4 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While literature on PAS diagnosis using [ 18 F]FDG-PET/CT is limited, the available reports suggest that FDG-avid splenic lesions are likely to be malignant angiosarcomas [5,[8][9][10]]. An exception is reported by Sözel et al, where splenic lesions showed FDG-avidity, but metastatic liver lesions were not hypermetabolic [11]. In the three cases presented here, all lesions originating from the malignant angiosarcoma in the spleen, liver, and bone were FDG-avid.…”

Section: Discussionmentioning

confidence: 99%

Primary splenic angiosarcoma: a case series of a rare oncological entity and diagnostic challenge

Dirven,

Leclercq,

D'Hondt

et al. 2024

View full text Add to dashboard Cite

Background and purpose: Primary angiosarcoma of the spleen (PAS), an exceptionally rare and aggressive neoplasm with high metastatic risk (70%–85%), is frequently diagnosed in an advanced or metastatic stage. It presents diagnostic challenges due to its nonspecific symptomatology and resemblance to benign vascular lesions in various imaging modalities. Patients and methods: This case series aims to clarify the diagnostic difficulties by comparing imaging characteristics (CT-scan, MRI, and [18F]FDG-PET/CT) as well as pathological findings of three PAS cases diagnosed in different stages of the diseases (localized, metastatic, and metastatic with organ failure). Furthermore, a brief review on diagnostic and therapeutic features is included. Results and interpretation: We suggest [18F]FDG-PET/CT as a differentiating tool between benign and malignant splenic lesions and propose a flowchart of a diagnostic algorithm for PAS. For treatment, we advocate for early splenectomy and when systemic therapy is warranted, paclitaxel emerges as a viable first-line option. While it is crucial to acknowledge that further trial data is required to evaluate the efficacy of emerging treatment regimens, designing and conducting trials for PAS is challenging given its scarcity and aggressive behavior. Therefore case reporting remains important.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary splenic angiosarcoma: a case series of a rare oncological entity and diagnostic challenge

Dirven,

Leclercq,

D'Hondt

et al. 2024

View full text Add to dashboard Cite

show abstract

Spleen angiosarcoma: a world review

Hsien

Shelat

2021

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma

Takehara

Miyamoto

Fujino

et al. 2021

Case Rep Gastroenterol

View full text Add to dashboard Cite

A primary splenic angiosarcoma is a rare type of soft tissue sarcoma and is associated with an extremely poor prognosis. In this study, we describe the case of a patient who was diagnosed with metastatic primary splenic angiosarcoma and survived for about 2 years. A 62-year-old female was referred to us for the treatment of splenic angiosarcoma with disseminated intravascular coagulation (DIC) and multiple liver and bone metastases. Paclitaxel therapy resulted in recovery from DIC and enabled her to continue sequential treatment through to sixth-line chemotherapy. We reviewed all splenic angiosarcoma case reports which were described as stage IV to date and compared with our case. From these data, we found that the median overall survival was 105 days, and the prognosis of splenic angiosarcoma of stage IV was worse than conventional case series. Splenectomy was performed in more patients than chemotherapy as a treatment. Moreover, various chemotherapeutic regimens were used. These data suggest that administering chemotherapy including paclitaxel to patients with splenic angiosarcoma might improve their prognosis.

show abstract

Primary Splenic Angiosarcoma with Liver Metastasis Caused by Malign Transformation of Hemangioma: A Case Report and Literature Review

Cited by 4 publications

References 10 publications

Primary splenic angiosarcoma: a case series of a rare oncological entity and diagnostic challenge

Primary splenic angiosarcoma: a case series of a rare oncological entity and diagnostic challenge

Spleen angiosarcoma: a world review

Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma

Contact Info

Product

Resources

About